Experimental evaluation of guideline-recommended pharmaceutical manipulations for hyperbolic tapering of psychiatric drugs.

Abstract

Hyperbolic tapering is increasingly recommended for the gradual reduction of psychiatric drugs to minimise withdrawal symptoms, yet available formulations rarely accommodate the small dose regimens required. To evaluate whether pharmaceutical manipulation strategies - as proposed in clinical guidelines for hyperbolic tapering - can produce progressively smaller haloperidol doses with adequate accuracy and precision. Strategies included whole and split tablets, liquid dispensed via dropper or dosing syringe, diluted solutions and tablet suspension, applied under controlled laboratory conditions. Haloperidol was used as a model, following an exponential 10% dose reduction schedule from 5 to 0 mg, generating multiple tapering steps that mirrored real-world scenarios. Drug content was quantified by high-performance liquid chromatography and interpreted according to an adapted pharmacopoeial criterion. All strategies yielded mean doses within 90-110% of expected values, demonstrating satisfactory accuracy and reproducibility. Variability was higher with tablet splitting, drop-based measurements and tablet suspension (relative standard deviation of 8.0%), whereas the use of whole tablets, dosing syringe and diluted liquid improved precision (relative standard deviation of 3.3%). These findings demonstrate the technical feasibility of achieving progressively smaller doses through standardised manipulation strategies, providing experimental support for hyperbolic tapering in clinical practice. Although off-label, such approaches currently offer the only practical means for safe dose reduction in the absence of smaller dose formulations, highlighting a regulatory gap between product design and clinical needs. Aligned with clinical guidelines, our findings support manipulation strategies as a practical and reliable component of individualised dose reduction in psychiatric care.